International Trade and Industry Minister Datuk Seri Mustapa Mohamed said the government was aware the matter was worrying to Malaysian as it would involved price hikes of drugs in the market.
"In this case, the main issue is to call for the 20-year patent period to be extended.
"When that occurs, it will delay the introduction of the generic drug and, thus, will increase the price of drugs. For Malaysia it is a vital issue and will stand firm on the matter," he told Bernama after attending a special briefing with the
Malaysian National News Agency (Bernama) staff here today.
Apart from Malaysia, he said, several other countries also rejected the proposal.
"So this public concern should not be prolonged as not all wanted to extend the patent period, there are several countries together with us, who strongly oppose such efforts," he said.
Drugs with expired patent period would be categorised as generic drug and could be produced by any companies, including local ones, offering much cheaper roices.
The TPPA negotiation involved Australia, Brunei, Chile, canada, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States and Vietnam.
At the TPPA ministerial level meeting in Singapore last February, seven matters were finetuned, including intellectual property rights.
没有评论:
发表评论